stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) Current ratio
Twist Bioscience Corporation's current ratio at the end of the quarter to 30 June 2026 was 2.7×, down 1.0× from fiscal 2025 (3.6×). Over the past ten years it has ranged from 3.6× (fiscal 2025) to 9.3× (fiscal 2020) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.6× | (25.41%) |
| FY2024 | 4.9× | (15.59%) |
| FY2023 | 5.8× | (12.05%) |
| FY2022 | 6.6× | (24.09%) |
| FY2021 | 8.7× | (6.75%) |
| FY2020 | 9.3× | 76.18% |
| FY2019 | 5.3× | 2.22% |
| FY2018 | 5.2× | (27.93%) |
| FY2017 | 7.2× | 5.26% |
| FY2016 | 6.8× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 2.7× | (0.89%) |
| Mar 2026 | 2.7× | (28.64%) |
| Dec 2025 | 3.8× | 3.71% |
| Sep 2025 | 3.6× | (6.65%) |
| 29 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 21.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| IBRX ImmunityBio, Inc. compare | 5.7× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 3.1× |
| TWST Twist Bioscience Corporation | 2.7× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TWST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement